Study of Undertreatment of Patients With Dyslipidemia in Bulgaria

AstraZeneca2,500 enrolled

Overview

The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.

Study Type

OBSERVATIONAL

Enrollment

2,500

Conditions

Dyslipidemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks * Signed Informed Consent Exclusion Criteria: * Informed Consent not provided

Locations (15)

Research Site

Blagoevgrad, Bulgaria

Research Site

Burgas, Bulgaria

Research Site

Haskovo, Bulgaria

Outcomes

Primary Outcomes

The number and percentage of patients achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines

Time frame: 6 months - one visit only, no follow-up visits

Secondary Outcomes

The number and percentage of subjects achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines for several subject subsets

Time frame: 6 months - one visit only, no follow-up visits

The number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated 2004 NCEP ATP III guidelines, overall and for several subject subsets

Time frame: 6 months - one visit only, no follow-up visits

The number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines [<130mg/dL (3,37mmol/L)], in the following sub-population: patients with fasting triglycerides >200 mg/dL

Time frame: 6 months - one visit only, no follow-up visits

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.